UNH: CMS Rate Boost Rescues a Broken Quarter
Key Takeaways
- CMS's 2027 Medicare Advantage rate increase of +2.48% adds roughly $3.9 billion in incremental revenue, well above the +0.09% initially proposed.
- UNH's Q4 2025 was near-zero earnings ($0.01 EPS) — the CMS boost doesn't fix 2025's cost problems but gives crucial margin relief for 2027.
- At $311 with projected 2028 EPS of ~$23, UNH trades at 13.6x forward earnings — buy in thirds around the April 21 earnings report for the best risk-reward.
UnitedHealth Group surged 10.7% to $311.44 on Tuesday after the Centers for Medicare & Medicaid Services finalised 2027 Medicare Advantage payment rates at a net +2.48% increase. Wall Street had expected roughly 1%. The initial January proposal was a paltry +0.09%. This is the single most important regulatory decision for managed care stocks, and CMS just handed UNH a lifeline.
The timing couldn't be better. UNH's Q4 2025 was a disaster — net income of $10 million on $113 billion in revenue, EPS of $0.011. Operating income collapsed to $380 million, down from $9.1 billion in Q1. The stock has been cut in half from its $606 high. One favorable CMS ruling doesn't fix the underlying cost pressures, but it gives management the margin relief they desperately need heading into 2027.
The question for investors: is today's rally a dead-cat bounce in a broken story, or the inflection point where UNH's earnings power starts recovering?
The CMS Decision: $3.9 Billion in Incremental Revenue
CMS's final 2027 Medicare Advantage rate increase of +2.48% dramatically exceeds both the proposed +0.09% and consensus expectations of roughly 1%. For UNH specifically, Seeking Alpha estimates this translates to approximately $3.94 billion in incremental annual revenue.
That's significant context. UNH's trailing four-quarter revenue totals $447.6 billion. An additional $3.9 billion is less than 1% of the top line. But Medicare Advantage is a high-volume, thin-margin business where small rate changes cascade through profitability. The difference between a 0.09% and 2.48% rate increase is the difference between margin compression and margin stabilisation.
The rate boost allows UNH to bid more aggressively for 2027 MA contracts, enhance supplemental benefits to attract members, and potentially stem the Medicare Advantage member losses that plagued 2025. It doesn't solve the utilisation cost problem overnight, but it buys time.
Q4 2025: The Quarter That Broke the Stock
UNH's earnings trajectory through 2025 tells a story of accelerating deterioration:
Q1 was strong: $6.91 EPS, 8.3% operating margin, $9.1 billion operating income. By Q4, operating income had cratered to $380 million — a 96% decline. Net income was functionally zero at $10 million.
The culprit is medical cost pressure. Cost of revenue rose from $85.8 billion in Q1 to $94.7 billion in Q4 while revenue grew just 3.3%. Gross margin compressed from 21.7% to 16.3%. Operating expenses also ballooned as UNH took charges related to the Change Healthcare cyberattack aftermath and elevated Medicare Advantage utilisation.
Management effectively wrote off Q4 to kitchen-sink the bad news. The $938 million tax benefit partially masked the operating collapse, but investors saw through it. The stock fell from above $500 to the $280 range.
Valuation: Cheap If Earnings Recover, Expensive If They Don't
At $311.44, UNH trades at 23.5x trailing earnings of $13.23 per share. That looks reasonable for a healthcare blue chip — until you realise those trailing earnings include a Q4 where the company earned essentially nothing.
The forward picture depends entirely on whether UNH can return to normalised profitability. Analyst estimates for 2028 project quarterly EPS ranging from $3.91 to $8.15, suggesting full-year earnings of roughly $22.87. At that level, UNH trades at 13.6x forward 2028 earnings — genuinely cheap for a company with $450 billion in revenue.
Price-to-book sits at 3.19x, and the dividend yield is 0.67%. The balance sheet carries $87.2 billion in debt against $103.4 billion in shareholders' equity — leveraged but manageable for a business generating $447 billion in annual revenue. The key metric to watch is the medical loss ratio: if utilisation costs stabilise, the earnings rebound could be dramatic.
The Recovery Thesis: What Has to Go Right
For UNH to justify its current price, three things need to happen. First, the CMS rate boost must translate into improved 2027 MA contract economics. UNH lost Medicare Advantage members in 2025 as it pulled back from unprofitable markets. The 2.48% rate increase gives pricing room to re-enter those markets competitively.
Second, medical cost trends must stabilise. The post-pandemic utilisation surge — deferred procedures, behavioural health demand, GLP-1 drug costs — has been the primary margin killer. Evidence suggests utilisation is plateauing, but UNH needs Q1 2026 data to confirm the trend.
Third, Optum must regain its growth trajectory. UNH's health services segment has been the company's growth engine, but the Change Healthcare integration disruptions and DOJ antitrust scrutiny have created operational headwinds. Earnings on April 21 will be the first test of whether Optum is back on track.
The risk is that all three conditions must be met simultaneously. The CMS rate increase alone, while positive, can't offset continued utilisation cost escalation or Optum margin pressure.
Positioning: The April 21 Earnings Catalyst
UNH reports Q1 2026 earnings on April 21 — two weeks away. This report will determine whether today's CMS-driven rally has legs or was a one-day event.
The market wants to see two things: a medical loss ratio that's stabilising (not still climbing), and forward guidance that incorporates the CMS rate boost. If management raises full-year guidance on the back of the rate decision, the stock has room to run toward $350-$375. If Q1 shows continued margin deterioration, today's rally becomes a selling opportunity.
UNH is still 49% below its all-time high of $606. The stock has a long way to recover even in a bullish scenario. For investors willing to hold through earnings volatility, the combination of a favourable CMS ruling and cheap forward earnings multiples makes UNH worth owning — but position sizing matters. This is a recovery bet, not a safe harbour.
Conclusion
The CMS rate decision is genuinely positive for UnitedHealth, adding approximately $3.9 billion in incremental 2027 revenue at a moment when the company desperately needs margin relief. Today's 10.7% rally is justified as a repricing of the 2027 earnings outlook.
But one regulatory tailwind doesn't erase a Q4 where EPS was $0.01. The April 21 earnings report is the real test. Investors with a 12-month horizon should consider building a position here, with the understanding that the next two weeks will be volatile. Buy in thirds: a starter position now, add on a post-earnings dip, and fill on confirmation of medical cost stabilisation. UNH at $311 with $22+ in projected 2028 earnings is the kind of asymmetric risk-reward that builds portfolios — if you can stomach the near-term uncertainty.
Frequently Asked Questions
Sources & References
www.benzinga.com
Disclaimer: This content is for informational purposes only and does not constitute financial advice. Consult qualified professionals before making investment decisions.